

Editorial

Human Immunodeficiency Virus Infection, Antiphospholipid Antibodies, and the Antiphospholipid Syndrome



Over recent years it has become evident that the spectrum of autoimmune and rheumatic diseases in patients with human immunodeficiency virus (HIV) infection is increasing¹⁻⁴ and includes conditions such as polymyositis/myopathies⁵⁻⁷, Sjogren's syndrome, Raynaud's phenomenon⁴, psoriatic arthritis, as well as primary biliary cirrhosis⁸, HIV-related vasculitis⁹, and Behcet's syndrome¹⁰.

Systemic lupus erythematosus (SLE) and sarcoidosis, however, in the HIV-infected population, seem to have a lower incidence than would be expected in the general population, although several cases of sarcoidosis, which is associated with depressed cellular immunity, have been documented in patients with AIDS. It is possible that the development of an autoimmune diathesis is suppressed by HIV infection and could be restored with therapy and normalization of CD4 counts with functional T cells. Indeed this hypothesis has been verified by the documentation of several such cases. Erdal, *et al*¹¹ reported a patient with HIV who developed SLE after the initiation of highly effective active retroviral treatment. Fox, *et al*¹² documented a female patient with SLE who developed HIV infection followed by clinical improvement and disappearance of autoantibodies. Thyrotoxicosis and thyroid autoantibodies have also been reported in a patient with HIV after restoration of immune function¹³ as has sarcoidosis, which has been reported in 2 patients following potent anti-HIV therapy^{14,15}.

Antiphospholipid antibodies (aPL) may be demonstrated during the course of many infections in addition to occurring in conditions such as SLE, primary antiphospholipid syndrome (APS), and a wide variety of other rheumatic diseases. Syphilis was the first infection to be linked with aPL: one of the components of the VDRL reagent (cardiolipin) being responsible for the original finding that antibodies thought initially to be directed against cardiolipin, were, in fact, pivotal in the pathogenesis and for the diagnosis of the APS. It was subsequently found, however, that these antibodies were directed against a number of serum proteins, primarily β_2 -glycoprotein I (β_2 -GPI) and prothrombin, the phospholipids modifying the protein molecules to create a "cryptic epitope" or neoantigen on the protein molecules that were revealed or formed only when these proteins were bound to certain anionic surfaces, e.g.,

gamma-irradiated polystyrene or anionic phospholipid membranes. Recent work by Roubey, *et al* has shed some light and offers another explanation of the relationship between anticardiolipin (aCL) and β_2 -GPI¹⁶. Certain IgG aCL recognize β_2 -GPI. Binding occurs when β_2 -GPI is immobilized on gamma irradiated polystyrene, on cardiolipin-coated polystyrene (as in the standard aCL ELISA) or on cardiolipin-containing liposomes, but not when the antigen is immobilized on untreated polystyrene. Antibody binding to β_2 -GPI coated on gamma-irradiated polystyrene seems to be dependent upon high antigen density and antibody valency. Autoantibodies to β_2 -GPI are of relatively low intrinsic affinity and there are other examples of this phenomenon (e.g., binding of IgM rheumatoid factors to aggregated IgG).

The major infection worldwide over the past 20 years has been HIV-induced infection and it is not surprising that this condition has been so extensively studied by immunologists and rheumatologists in view of its eventual destruction of the patient's immune system with resultant major "autoimmune" complications.

ANTIBODIES TO PHOSPHOLIPIDS IN HIV INFECTION

HIV infection is associated with many abnormalities in B cell function resulting in the production of a large variety of autoantibodies that include anti-alpha myosin, antibodies to endogenous erythropoietin, denatured DNA, thyroid peroxidase, and TSHR. However the antibodies most frequently found are those directed towards cardiolipin and those responsible for lupus anticoagulant (LAC) positivity¹⁷. LAC were first described in 44% of patients with acquired immunodeficiency syndrome (AIDS) and in 43% of asymptomatic HIV positive individuals (they were found to be transient by Bloom, *et al* in 1986¹⁸). In 1997, Canoso, *et al* reported on aCL positivity with HTLV -111 infection¹⁹. In 1992, the association of aCL with HIV infection in male homosexuals was reported²⁰ and several studies since then have confirmed these original findings. Daroca, *et al*²¹ tested 84 HIV-infected patients in the same year and found that 59.5% of the 84 patients were IgG aCL positive. None had any thromboembolic phenomena. No significant differ-

ences were found with respect to sex, risk factors, and stage of the disease. They stated that the aCL did not appear to be a prognostic marker in HIV-infected subjects but were indicative of impaired humoral immunity found in these patients. Falco, *et al*²² in 1993 examined 39 HIV positive and 20 aCL positive SLE sera and found that, in the HIV sera, reduced binding was evident if the co-factor (β_2 -GPI) was added. In the SLE sera, however, addition of the co-factor improved the binding. These authors concluded that the aCL in HIV infection appeared to have a different specificity to those found in SLE. Weiss, *et al*²³, in 1995 found aCL in 47% of HIV positive individuals, and other authors have also confirmed this association²⁴⁻²⁷.

The aCL described in HIV patients are of both the pathogenic (β_2 -GPI cofactor dependent) and the infectious type (β_2 -GPI independent). Both types of aCL may be detected following several different types of infections. The isotypes and diversity of the aPL may also vary and may include antibodies to phosphatidylserine. The frequency of antibodies to prothrombin and β_2 -GPI is significantly less in HIV patients according to Guerin, *et al*²⁸. These investigators found LAC positivity in 72% and aCL positivity in 67% of their patients. A previous paper by the same authors demonstrated significantly elevated antibodies to β_2 -GPI in patients with definite APS but only in 10% of those with HIV infection. The detection of anti-prothrombin antibodies was significantly less in their HIV patients, but recent work by Loizou, *et al*²⁹ demonstrated a high frequency of antibodies to prothrombin in a group of 100 HIV positive black patients in South Africa. These variations in aPL (particularly antiprothrombin antibodies) in the study population may be due to the different strain of HIV encountered and predominating in infected African patients. The antigen used in the ELISA performed in these patients was prothrombin alone. The findings regarding β_2 -GPI were subsequently confirmed by Petrovas, *et al*²⁵, who investigated the phospholipid specificity, avidity, and reactivity with β_2 -GPI in 44 patients with HIV infection compared with 6 patients with SLE with secondary APS, 30 SLE patients without APS, and 11 patients with primary APS. The prevalence of aCL, antiphosphatidylserine, antiphosphatidylinositol, and antiphosphatidylcholine (36%, 56%, 34%, and 43%, respectively) was similar to that found in the SLE/APS and primary APS patients. The prevalence of these antibodies was significantly higher than that observed in SLE/non-APS patients. However, anti- β_2 -GPI antibodies were detected in only 5% of the HIV-1 infected patients in this series. A significant decrease of aPL binding after treatment with urea and NaCl was observed in the sera of HIV-1 infected patients compared with APS patients, indicating that aPL from HIV patients have a low resistance to dissociating agents indicating low avidity of the antigen. Gonzales, *et al*²⁶ were also unable to detect anti- β_2 -GPI in their HIV positive sera despite the presence of high concentrations of aCL.

In 1996, Silvesteris, *et al*²⁷ studied antibodies to phosphatidylserine in HIV patients among a panel of phospholipid antigens. They found that *in vitro* apoptosis of T cells was increased in patients with high serum anti-phosphatidylserine IgG. Together with other studies they concluded that, because phosphatidylserine is exteriorized by apoptotic lymphocytes, its persistence may cooperate with macrophages in the clearance of dead cells by an enhanced antibody-dependent cellular cytotoxicity mechanism and they postulated that this might explain the absence of thrombophilia in HIV positive patients with elevations of the aPL.

THROMBOEMBOLIC DISEASE AND HIV INFECTION

There are many reports of thrombosis occurring in patients with HIV/AIDS and these include peripheral vein^{30,31}, pulmonary embolism³¹, retinal vein³²⁻³⁵, cerebral vein³⁶, portal vein³⁷, and mesenteric^{38,39} occlusions. Both arterial and venous thromboembolic disease have been reported in one patient by Bosson, *et al*⁴⁰. There are many reasons for the existence of the hypercoagulable state in some HIV patients and these have recently been very ably reviewed in the HIV literature by Saif and Greenberg⁴¹. These authors also reported a retrospective study of 131 patients⁴². Not only may aPL (antibodies to cardiolipin and other negatively charged autoantibodies, LAC) be found, but increased levels of von Willebrand factor, and deficiencies of protein C, protein S, antithrombin III and heparin cofactor II have also been detected⁴³ in HIV sera.

Opportunistic infections with cytomegalovirus (CMV)^{36,44-46} or, on occasion, *Pneumocystis carinii*⁴⁷ have, in several reported cases, also been associated with thrombosis. CMV has been demonstrated locally within affected tissues (digital infarcts) by Smith, *et al*⁴⁴, as well as in blood. This is not unique to HIV infected individuals, as CMV infection has also been associated with thrombosis following liver transplantation⁴⁸. Masala, *et al*⁴⁷ demonstrated cross-reactions between *P. carinii* infections and cardiolipin similar to that previously reported by Misra, *et al*⁴⁹ in patients with infectious mononucleosis and aCL. They observed that in patients with AIDS, aCL occurred almost exclusively among those who had active *P. carinii* pneumonia.

Treatment with protease-inhibitor therapy, which causes major lipid disturbances such as hypercholesterolemia, hypertriglyceridemia, and insulin resistance has also been documented as causing deep vein thrombosis and pulmonary emboli in otherwise healthy, HIV-infected patients, as reported by George, *et al*⁵⁰. Carr reported portal vein thrombosis in a patient receiving indinavir therapy³⁷ and the use of megestrol acetate has also been associated with a tendency to thrombosis^{51,52}.

An epidemiological review by Sullivan, *et al* in 2000⁵³

reported that many occurrences of thrombosis may have been asymptomatic and that dehydration and debilitation or an advanced stage of the disease itself may have been contributing factors to the development of thrombosis.

Protein C, a vitamin K dependent protein that functions as a natural anticoagulant inactivates the procoagulant factors Va and VIIa. Decreased levels of functional protein C as well as antigenic protein C have been found in HIV-infected patients and these levels correlate with the degree of immunosuppression as determined by reduced CD4 cell counts, as reported by Feffer, *et al*⁵⁴ and by Sarif, *et al* in one of their series⁴⁰.

Heparin cofactor II (HCII) is a specific thrombin inhibitor, the inhibitory activity of which is enhanced by heparin. Zon and Groopman⁵⁵ found a higher prevalence of HCII deficiency in AIDS patients compared to other patients with similar CD4 counts. Reduced synthesis of the protein, the presence of an inhibitor or endothelial cell abnormalities may be possible explanations for this finding⁵⁶. Antithrombin III, an hepatocyte-synthesized serine protease inhibitor that neutralizes all the serine proteases (factors IIa, Xa, XIa, XIIa) has also been reported to be deficient in HIV patients who experience thrombotic events. Malnutrition or HIV-related nephropathy with loss of this factor in the urine may be the etiology in some patients⁵⁷.

Acquired deficiency of protein S has been reported in 31–76% of HIV infected patients⁵⁷⁻⁵⁹, and one study has correlated this with advanced disease⁵⁸. The protein S deficiency secondary to HIV infection involves both free and total protein S antigen. Bissuel, *et al*⁵⁸ correlated free protein S levels with high β_2 -microglobulin values, low CD4 positive counts, and elevated urine neopterin concentrations; they concluded that free protein S deficiency may coincide with the development of AIDS. Normal levels of C4b-binding protein have been found, suggesting that the mechanism for this reduction in protein S is different from that which occurs with inflammation. It seems that disturbances of endothelial cell function may be responsible. However, Sorice, *et al*⁶⁰ suggested that specific autoantibodies directed against protein S might be responsible for the lowering of the free protein S levels. Hassel, *et al*⁶¹ and Ordi, *et al*⁶² also studied this association and drew attention to anti-protein S in HIV infected patients.

HIV AND MANIFESTATIONS OF THE ANTIPHOSPHOLIPID SYNDROME

It has become clear that in HIV infection, both types of aCL (the pathogenic, β_2 -GPI dependent as well as the nonpathogenic, non- β_2 -GPI dependent) antibodies may be detected and that there is diversity, not only of the isotypes, but also of the aPL including anti-protein S antibodies.

In addition, there is a low frequency of antibodies directed towards β_2 -GPI in HIV-infected patients. It is there-

fore not surprising that the APS and its manifestations are infrequent in HIV. Certainly thrombotic and other manifestations are much more frequently encountered than with other viral infections, again pointing to a major immunological disturbance in HIV in contrast to other viral conditions^{63,64}. However, CMV infections have also been reported as being associated with the APS^{65,66}.

aCL and stroke in an HIV positive patient was reported by Thirumalai and Kirshner in 1994⁶⁷ and by Keeling, *et al*⁶⁸. Deep vein thrombosis of the extremities by Orbe-Rios, *et al*⁶⁸, and skin necrosis by Soweid, *et al*⁶⁹. Skin necrosis was also recently reported by Leder, *et al*⁷⁰ in a male patient with HIV who suffered from testicular infarction requiring orchidectomy. A 42-year-old woman with a 12 year history of HIV infection and who developed gangrene of both forefeet was reported by Cailleux, *et al*⁷¹. A skin biopsy revealed intracapillary thrombi and severe necrosis of the hypodermis with no evidence of vasculitis. IgG aCL concentrations were elevated.

A 33-year-old woman with AIDS who had had a cerebrovascular accident and who developed a splenic infarction was documented by Cappell, *et al* in 1993⁷². A recent report has also drawn attention to aPL associated complications and APS in HIV infection. Turhal, *et al*⁷³ reported 4 cases. The first developed livedo reticularis acutely; the second, probable avascular necrosis of the femoral head associated with demonstrable decreased blood flow; the third, thrombosis of the inferior vena cava and pulmonary emboli; and the fourth, a major pulmonary embolus. Avascular necrosis of bone (AVN) has been previously documented with HIV infection. Belmonte, *et al* reported 3 cases of AVN associated with aPL in 1993⁷⁴. No risk factors other than the presence of aPL were present in these patients. However, several other subsequent reviews of the association failed to detect aPL as a risk factor in this condition⁷⁵⁻⁸⁰. It is likely that hyperlipidemia (associated with antiretroviral therapy)⁷⁹, corticosteroid use, and alcohol abuse represent some of the risk factors in the pathogenesis of the condition, with aCL being present in a minority only. Pulmonary hypertension seen with APS may also be an aPL-related complication.

The incidence of HIV-associated pulmonary hypertension (PHT) is estimated to be 1/200, which is much higher than the 1/200,000 found in the general population⁸¹. The common reasons for PHT encountered in HIV-infected patients are pulmonary infections, venous thromboembolism, and left ventricular dysfunction. However, "primary" PHT has been reported in some patients without a history of thromboembolic disease, intravenous drug usage, or pulmonary infections. Its pathogenesis remains poorly understood and it has been hypothesized that HIV causes endothelial cell damage and mediator-related vasoconstriction through stimulation by the envelope gp 120, including direct release and effects of endothelin-1, the most potent vasoconstrictor, and by the effects of interleukin 6

and tumor necrosis factor- α , on the pulmonary arteries themselves. It is well established that the frequency of aCL is elevated in patients with "primary" PHT, but the frequency of aCL elevations in the HIV group remains to be elucidated.

Thrombotic thrombocytopenic purpura (TTP) is a rare but well described complication of HIV infection, occurring equally frequently during the early asymptomatic phase of HIV infection as well as with clinical AIDS, the clinical spectrum varying from a low grade asymptomatic thrombocytopenia with mild renal insufficiency to a severe illness with major neurological manifestations and renal failure that may require dialysis⁸²⁻⁸⁵. Indeed the presence of von Willebrand factor-cleaving protease inhibitor, which may be involved in the pathogenesis of TTP, has been described in the plasma of a patient with both AIDS and TTP⁸⁶. Thrombotic microangiopathy (TMA) encompassing microangiopathic hemolytic anemia, thrombocytopenia, and renal failure is another renal complication that may develop in patients with HIV⁸⁷. This type of vascular lesion is more common in HIV patients than in the normal population, may be one of the first manifestations of HIV infection, and may be severe⁸⁸. TTP has been infrequently associated with aPL, but TMA is relatively common in patients with APS. The association of both these conditions in HIV/AIDS patients, as yet, has also not been investigated and reported.

Questions of paramount importance and interest include the pathogenicity of the various types of aPL and why thrombosis is seen in selected patients with SLE only and very infrequently with infections. The recent work of Sheng, *et al*⁸⁹, which measured the effects of test antibody or plasma samples on *in vitro* thrombin formation, will clearly be extended and may provide some clear information concerning this problem. These investigators found that plasma and affinity purified antibodies from patients with APS inhibited thrombin generation significantly more so than from patients with aPL from other causes; moreover, APS patient samples showed thrombin inhibition in the presence of anti- β_2 -GPI or antiprothrombin antibodies.

In summary, it seems that the pathogenesis of thrombotic complications in patients with HIV infection and AIDS is multifactorial, with the aPL playing a role in selected patients only. The frequency of thrombotic complications encountered with aPL positivity, while several cases have been published from various centers, remains low at this time. Lipid disturbances after antiretroviral therapy (now increasingly available from drug companies at reduced cost) and their attendant vascular complications will no doubt overtake hematological and immunological disturbances seen in these patients, as a cause of these complications. However, discovery of new classes of anti-retroviral compounds (e.g., fusion inhibitors, integrase inhibitors) will diminish usage of the protease inhibitor

class of drugs, which seem to be mostly linked with these complications, thereby overcoming these iatrogenic problems.

RONALD A. ASHERSON, MD, FACP, FRCP(Lond), MD(Hon), FCP(SA), FACR, Rheumatic Diseases Unit, The University of Cape Town School of Medicine and the Groote Schuur Hospital, Cape Town, South Africa;

YEHUDA SHOENFELD, MD, The Chaim Sheba Medical Centre, Tel Hashomer, Israel.

Supported by the Carole and Geoffrey Lawson Trust, United Kingdom. Address reprint requests to Dr. Asherson, the Rosebank Clinic, 14 Sturdee Avenue, Rosebank, Johannesburg, South Africa 2196.

REFERENCES

1. Reveille JD. The changing spectrum of rheumatic disease in human immunodeficiency virus infection. *Semin Arthritis Rheum* 2000;30:147-66.
2. Berman A, Espinoza LR, Diaz JD, et al. Rheumatic manifestations of human immunodeficiency virus infection. *Am J Med* 1988;85:59-64.
3. Calabrese LH, Kelley DM, Myers A, et al. Rheumatic symptoms and human immunodeficiency virus infection: The influence of clinical and laboratory variables in a longitudinal cohort study. *Arthritis Rheum* 1991;34:257-63.
4. Munoz-Fernandez S, Cardenal A, Balsa A, et al. Rheumatic manifestations in 556 patients with human immunodeficiency virus infection. *Semin Arthritis Rheum* 1991;21:30-9.
5. Cuellar ML. HIV infection-associated inflammatory musculoskeletal disorders. *Rheum Dis Clin North Am* 1998;24:403-21.
6. Dalakas MC, Pezeshkpour GH. Neuromuscular diseases associated with human immunodeficiency virus infection. *Ann Neurol* 1988;23 Suppl:S38-48.
7. Gresh JP, Aguilar JL, Espinoza LR. Human immunodeficiency virus infection-associated dermatomyositis. *J Rheumatol* 1989;16:1397-8.
8. Mason AL, Xu L, Guo L, et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. *Lancet* 1988;351:1620-4.
9. Gheradi R, Belec L, Mhiri C, et al. The spectrum of vasculitis in human immunodeficiency virus-infected patients: a clinicopathologic evaluation. *Arthritis Rheum* 1993;36:1164-74.
10. Routy JP, Blanc AP, Viallet C, et al. A rare cause of arthritis, Behcet's disease in a HIV-positive subject, 69 years of age [French]. *Presse Med* 1989;18:525-8.
11. Erdal D, Lipsky PE, Berggren RE. Emergence of systemic lupus erythematosus after initiation of highly active anti-retroviral therapy for human immunodeficiency virus infection. *J Rheumatol* 2000;27:2711-4.
12. Fox RA, Eisenberg DA. Human immunodeficiency virus infection in systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1168-72.
13. Jubault V, Penfornis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1 infected patients. *Clin Endocrinol Metab* 2000;85:4254-7.
14. Zandman-Goddard G, Peeva E, Barland P. Combined autoimmune disease in a patient with AIDS. *Clin Rheumatol* 2002;21:70-2.
15. Blanche P, Passeron A, Gombert B, Ginsburg C, Salmon D, Sicard D. Sarcoidosis and HIV infection: influence of highly active retroviral therapy [letter]. *Br J Dermatol* 1999;140:1185.

16. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize B2-glycoprotein I in the absence of phospholipid. *J Immunol* 1995;154:954-96.
17. Massabki PS, Accetturi C, Nishie IA, da Silva NP, Sato EI, Andrade LE. Clinical implications of autoantibodies in HIV infection. *AIDS* 1997;11:1845-50.
18. Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. *JAMA* 1986;258:491-3.
19. Canoso RT, Zon LI, Groopman JE. Anticardiolipin antibodies associated with HTLV-111 infection. *Br J Haematol* 1987; 65:495-8.
20. Argov S, Shattner Y, Burstein R, Handzel ZT, Shoenfeld Y. Autoantibodies in male homosexuals and HIV infection. *Immunol Lett* 1991;30:31-6.
21. Daroca J, Gutierrez-Cebollada J, Yazbeck H, Berges A, Rubies-Prat J. Anticardiolipin antibodies and acquired immunodeficiency syndrome: prognostic marker or association with HIV infection? *Infection* 1992;20:140-2.
22. Falco M, Sorrenti A, Priori R, et al. Anticardiolipin antibodies in HIV infection are true antiphospholipids not associated with antiphospholipid syndrome. *Ann Ital Med Int* 1993;8:171-4.
23. Weiss L, You J-F, Giarral P, Alhenc-Gelas M, Senger D, Kazatchkine MD. Anticardiolipin antibodies are associated with anti-endothelial cell antibodies but not with anti-beta 2 glycoprotein I antibodies in HIV infection. *Clin Immunol Immunopathol* 1995;77:69-74.
24. De Larranaga GF, Forastoero RR, Carrera LC, Alonso BS. Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndrome. *Thromb Res* 1999;95:19-25.
25. Petrovas C, Vlachoyiannopoulos PG, Kordossis T, Moutsopoulos HM. Antiphospholipid antibodies in HIV infection and SLE with or without antiphospholipid syndrome; comparisons of phospholipid specificity, avidity and reactivity with beta 2-GPI. *J Autoimmun* 1999;123:347-55.
26. Gonzales C, Leston A, Garcia-Berrocal B, et al. Antiphosphatidylserine antibodies in patients with autoimmune diseases and HIV-infected patients: effects of Tween 20 and relationship with antibodies to beta 2-glycoprotein I. *J Clin Lab Anal* 1999;13:59-64.
27. Silvestris F, Frassanito MA, Cafforio P, Potenza D, Di Loreto M, Tucci M. Antiphosphatidylserine antibodies in human immunodeficiency virus-1 patients correlate with evidence of T-cell apoptosis and mediate antibody-dependent cellular cytotoxicity. *Blood* 1996;87:5185-95.
28. Guerin J, Casey E, Feighery, et al. Anti-B2 GPI antibody isotype and IgG subclass in antiphospholipid syndrome patients. *Autoimmunity* 1999;31:109-16.
29. Loizou S, Singh S, Wypkema E, Asherson RA. IgG, IgH and IgA aPL in Black South African infectious disease patients [abstract]. *Lupus* 2002;11:570.
30. Becker DM, Saunders TJ, Wispelway B, Schain DC. Case report: venous thromboembolism in AIDS. *Am J Med Sci* 1992;303:395-7.
31. Tanimowo M. Deep vein thrombosis as a manifestation of acquired immunodeficiency syndrome. *Centr Afr J Med* 1996;42:327-8.
32. Roberts SP, Haefs TMP. Central retinal vein occlusion in a middle aged adult with HIV infection. *Optom Vis Sci* 1992;69:567-9.
33. Mansour AM, Li H, Segal EL. Picture resembling hemispherical retinal vein occlusion in acquired immunodeficiency syndrome: is it related to cytomegalovirus? *Ophthalmologica* 1996;210:108-11.
34. Park KL, Marx JL, Lopez PF, Rao NA. Noninfectious branch retinal vein occlusion in HIV-positive patients. *Retina* 1997; 17:162-4.
35. Friedman SM, Margo CE. Bilateral central retinal vein occlusions in patient with acquired immunodeficiency syndrome. *Arch Ophthalmol* 1995;113:1184-6.
36. Meyohas MC, Roulet E, Rouziquix C, et al. Cerebral venous sinus thrombosis and dual primary infection with human immunodeficiency virus and cytomegalovirus. *J Neurol Neurosurg Psychiatry* 1998;52:1010-1.
37. Carr A, Brown D, Cooper DA. Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor. *AIDS* 1997; 11:1657-8.
38. Narayanan TS, Narawane NM, Phadke AY, Abraham P. Multiple abdominal venous thrombosis in HIV positive patient. *Indian J Gastroenterol* 1998;17:105-6.
39. Wang L, Molina CP, Rajaraman S. Intestinal infarction due to vascular catastrophe in an HIV-infected patient. *AIDS Read* 2000;10:718-21.
40. Bosson JL, Fleury-Feullaide ML, Farah I, Leclerc P. Arterial and venous thromboembolic disease in an HIV positive patient. *J Mal Vasc* 1995;20:136-8.
41. Saif WS, Greenberg B. HIV and thrombosis: A review. *AIDS Patient Care STDS* 2001;15:15-24.
42. Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. *AIDS Patient Care and STDS* 2001;15:311-20.
43. Abouafia DM, Misuyasu RT. Haematologic abnormalities in AIDS. *Haemat Oncol Clin North Am* 1991;5:195-209.
44. Smith KJ, Skelton HG, Yeager J. Cutaneous thrombosis in human immunodeficiency virus type-1 positive patients and cytomegalovirus viraemia. *Arch Dermatol* 1995;131:357-8.
45. Bagley PH, Scott DA, Smith LS, et al. Cytomegalovirus infection, ascending myelitis and pulmonary embolus [letter]. *Ann Intern Med* 1986;104:587.
46. Jenkins RE, Peters BS, Pinching AJ. Thromboembolic disease in AIDS is associated with cytomegalovirus disease. *AIDS* 1991;5:1540-2.
47. Powers P, Stahl-Bayliss CM. Cytomegalovirus thrombophlebitis after successful DHPG therapy. *Ann Intern Med* 1987;106:632-3.
48. Masala C, Sorice M, Di Prima MA, et al. Anticardiolipin antibodies and *Pneumocystis carinii* pneumonia [letter]. *Ann Intern Med* 1989;110:749.
49. Misra R, Venables PJ, Watkins RP, Maini RN. Autoimmunity to cardiolipin in infectious mononucleosis [letter]. *Lancet* 1987;2:629.
50. George SL, Swindells S, Knudson R. Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases. *Am J Med* 1999;107:624-62.
51. Prescribing information for megestrol acetate tablets. In: Physicians desk reference. Montvale, NJ: Medical Economics Company; 1968.
52. Hirsh J, Hull RD, Raskob GE. Epidemiology and pathogenesis of venous thrombosis. *J Am Coll Cardiol* 1986;8:104B-113B.
53. Sullivan PS, Dworkin MS, Jones JL, Hooper W. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. *AIDS* 2000;14:321-4.
54. Feffer SE, Fox FL, Orsen MM, et al. Thrombotic tendencies and correlation with clinical status in patients infected with HIV. *South Med J* 1995;88:1126-30.
55. Zon I, Groopman JE. Hematologic manifestations of the human immunodeficiency virus. *Semin Haematol* 1988;25:208-18.
56. Toulon P, Lamine M, Ledjev I, et al. Heparin cofactor 11 deficiency in patients infected with human immunodeficiency virus. *Thromb Haemost* 1993;70:730-1.
57. Stahl CP, Wideman CS, Spira TJ, Haff EV, Hixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. *Blood* 1993;81:1801-7.
58. Bissuel F, Berruyer M, Causse X, et al. Acquired protein S deficiency: Correlation with advanced disease in HIV-1 infected patients. *J Acq Immune Defic Syndr* 1992;5:484-9.
59. Culpepper RM, Carr AE. Case report: a novel form of free protein

- S deficiency in an HIV-positive patient on haemodialysis. *Am J Med Sci* 1992;303:402-4.
60. Sorice M, Griggi T, Arcieri P, et al. Protein S and HIV infection. The role of anticardiolipin and antiprotein S antibodies. *Thromb Res* 1994;73:165-75.
 61. Hassell KL, Kressin DC, Neumann A, Ellison R, Marlar RA. Correlation of antiphospholipid antibodies and protein S deficiency with thrombosis in HIV-infected men. *Blood Coag Fibrinolysis* 1994;5:455-62.
 62. Ordi J, Selva A, Monegal F, Porcel JM, Martinez-Costa X, Vilardell M. Protein S and HIV infection. The role of anticardiolipin and anti-protein S antibodies. *J Rheumatol* 1993;8:1321-4.
 63. Pulik M, Lefebvre d'Helencourt S, Coudere LJ. Unexplained venous thrombotic disease in HIV-infected patients. *J Acquir Immune Defic Syndr* 1992;5:484-9.
 64. Pinilla J, Hill AR. Thromboembolism associated with acquired immunodeficiency syndrome [letter]. *Chest* 1992;102:16.
 65. Uthman T, Tabbarah Z, Gharavi AE. Hughes syndrome associated with cytomegalovirus infection. *Lupus* 1999;8:775-7.
 66. Labarca JA, Rabagliati RM, Radrigan FJ, Rojas PP, Perez CM, Ferres MV. Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review. *Clin Infect Dis* 1997;24:197-200.
 67. Thirumalai S, Kirshner HS. Anticardiolipin antibody and stroke in an HIV-positive patient. *AIDS* 1994;8:1019-20.
 68. Orbea-Rios L, Venero Gomez E, Justo AI, Panes M, Comenereo Camacho J, Rodriguez P. Deep venous thrombosis of inferior extremity in a patient with AIDS and anticardiolipin antibodies [letter]. *An Med Interna* 1999;16:268.
 69. Soweid AM, Hajjar RR, Hewan-Lowe KO, Gonzalez EB. Skin necrosis indicating antiphospholipid syndrome in a patient with AIDS. *South Med J* 1995;88:786-8.
 70. Leder AN, Flansbaum B, Zandman-Goddard G, Asherson RA, Shoenfeld Y. Antiphospholipid syndrome induced by HIV. *Lupus* 2001;10:370-4.
 71. Cailleux N, Marie I, Jeanton M, Lecomte F, Levesque H, Courtois H. Are antiphospholipid antibodies pathogenic in the course of human immunodeficiency virus infection? *J Mal Vasc* 1999;24:53-6.
 72. Cappell MS, Simon T, Tiku M. Splenic infarction associated with anticardiolipin antibodies with acquired immunodeficiency syndrome. *Dig Dis Sci* 1993;38:1153-5.
 73. Turhal NS, Peters VB, Rand JH. Antiphospholipid syndrome in HIV infection — report on four cases and review of the literature. *ACI Int* 2001;13:268-71.
 74. Belmonte MA, Garcia-Portales R, Domenech I, Fernandez-Nebro A, Camps MT, De Ramon E. Avascular necrosis of bone in human immunodeficiency virus infection and antiphospholipid antibodies. *J Rheumatol* 1993;20:1424-8.
 75. Tigges S, Meli RJ. Osteonecrosis with HIV infection. *Can Assoc Radiol J* 1995;46:280-4.
 76. Rademaker J, Dobro JS, Solomon G. Osteonecrosis and human immunodeficiency virus infection. *J Rheumatol* 1997;24:601-4.
 77. Blacksins MF, Kloster PC, Simon J. Avascular necrosis in human immunodeficiency virus infected patients. *Clin Imaging* 1999;23:314-8.
 78. Scribner AN, Troia-Cancio PV, Cox BA, et al. Osteonecrosis in HIV: A case-control study. *J Acquir Immun Def Syndr* 2000;25:19-25.
 79. Monier P, McKown K, Bronze MS. Osteonecrosis complicating highly active antiretroviral therapy in patients infected with human immunodeficiency virus. *Clin Infect Dis* 2000;31:1488-92.
 80. Mehta NJ, Khan IA, Mehta RN, Sepkowitz A. HIV-related pulmonary hypertension. Analytic review of 131 cases. *Chest* 2000;118:1133-41.
 81. Barbaro G. Cardiovascular manifestations of HIV infection. *J Roy Soc Med* 2001;94:384-90.
 82. Sood R, Rakkar AS, Carmosino L, Mir T, Khan FA. Thrombotic thrombocytopenic purpura in HIV infection: a report of two cases. *AIDS Patient Care STDS* 1996;10:349-52.
 83. Godwin JH, Kripas C. HIV/AIDS case histories: diagnostic problems. Thrombotic thrombocytopenic purpura. *AIDS Patient Care STDS* 1996;10:303.
 84. Viale P, Pagani L. Thrombotic thrombocytopenic purpura (TTP) during the course of HIV infection. *AIDS Patient Care STDS* 1997;4:302-3.
 85. Gruszecki AC, Wehrli G, Ragland BD, et al. Management of a patient with HIV infection-induced anaemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura. *Am J Haematol* 2002;69:229-31.
 86. Sahud MA, Claster S, Liu L, Ero M, Harris K, Furlan M. von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. *Br J Haematol* 2002;116:909-11.
 87. Sacristan Lista F, Saavedra Alonso AJ, Oliver Morales J, Vasquez Martul F. Nephrotic syndrome due to thrombotic microangiopathy (TMA) as the first manifestation of human immunodeficiency virus infection: recovery before antiretroviral therapy without specific treatment against TMA. *Clin Nephrol* 2001;55:404-7.
 88. Abraham B, Baud O, Bonnet E, et al. Thrombotic microangiopathy during HIV infection. A retrospective study performed in infectious diseases units in southern France. *Presse Med* 2001;30:581-5.
 89. Sheng Y, Hanly JG, Reddel SW, et al. Detection of 'antiphospholipid' antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding beta(2)-glycoprotein I and prothrombin. *Clin Exp Immunol* 2001;124:502-8.